Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International : successfully completes clinical validation for DiviTum® TKa FDA submission

share with twitter share with LinkedIn share with facebook
08/26/2020 | 12:34pm EDT

Biovica today announces that the clinical validation of the blood test DiviTum® TKa has been completed, demonstrating the clinical value of the product. The clinical validation is the final part of Biovica’s application for US market approval. Biovica remains on schedule to submit its regulatory filing during September 2020.

“We are very pleased that we have successfully completed the clinical validation in accordance with our timeline. DiviTum® TKa has met its predefined criteria. In the clinical validation, more than 1.700 samples from over 400 patients were analyzed. This is an important step towards finalizing our 510(k) application. This is a major milestone in making the product available for monitoring treatment of metastatic breast cancer and our intention is that DiviTum® TKa should be available to patients in the US early next year," said Anders Rylander, CEO of Biovica.

© Modular Finance, source Nordic Press Releases


share with twitter share with LinkedIn share with facebook
All news about BIOVICA INTERNATIONAL AB (PUBL)
10/30BIOVICA INTERNATIONAL : FDA resource reallocation impacts DiviTum®TKa timeline
AQ
10/23BIOVICA INTERNATIONAL : DiviTum®TKa in four posters at SABCS
AQ
09/25BIOVICA INTERNATIONAL : completes 510(k) submission for DiviTum®TKa to the FDA
AQ
08/27BIOVICA INTERNATIONAL : Bulletin from the annual general meeting in Biovica
AQ
08/27BIOVICA Q1 INTERIM REPORT : May-July 2020/2021
AQ
08/26BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..
AQ
08/26BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..
AQ
08/26BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..
AQ
07/22BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
AQ
06/30BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
AQ
More news
Financials
Sales 2021 19,5 M 2,19 M 2,19 M
Net income 2021 -32,5 M -3,66 M -3,66 M
Net cash 2021 6,50 M 0,73 M 0,73 M
P/E ratio 2021 -23,5x
Yield 2021 -
Capitalization 922 M 104 M 104 M
EV / Sales 2021 46,9x
EV / Sales 2022 20,7x
Nbr of Employees 21
Free-Float 70,3%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 31,00 SEK
Last Close Price 32,60 SEK
Spread / Highest target -4,91%
Spread / Average Target -4,91%
Spread / Lowest Target -4,91%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOVICA INTERNATIONAL AB (PUBL)176.27%104
EXACT SCIENCES CORPORATION33.90%18 627
GUARDANT HEALTH, INC.36.50%10 625
BGI GENOMICS CO., LTD.116.89%8 822
ADAPTIVE BIOTECHNOLOGIES CORPORATION54.01%6 257
SEEGENE INC--.--%6 007